| Identification | Back Directory | [Name]
4-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-((1r,4r)-4-hydroxycyclohexylamino)benzamide | [CAS]
908112-43-6 | [Synonyms]
CS-345
SNX-2112
PF 04928473
SNX-2112 (PF-04928473)
PF-04928473;PF 04928473
4-(6,6-Dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-((1r,4r)-4-hyd
4-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydroindazol-1-yl)-2-((1r,4r)-4-hydroxycyclohexylamino)benzamide
4-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-((1r,4r)-4-hydroxycyclohexylamino)benzamide
2-[(trans-4-Hydroxycyclohexyl)amino]-4-[4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo-3-(trifluoromethyl)-1H-indazol-1-yl]benzamide
Benzamide, 2-[(trans-4-hydroxycyclohexyl)amino]-4-[4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo-3-(trifluoromethyl)-1H-indazol-1-yl]-
SNX-2112;4-(6,6-DIMETHYL-4-OXO-3-(TRIFLUOROMETHYL)-4,5,6,7-TETRAHYDRO-1H-INDAZOL-1-YL)-2-((1R,4R)-4-HYDROXYCYCLOHEXYLAMINO)BENZAMIDE
4-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-((1r,4r)-4-hydroxycyclohexylamino)benzamide USP/EP/BP | [Molecular Formula]
C23H27F3N4O3 | [MDL Number]
MFCD16038907 | [MOL File]
908112-43-6.mol | [Molecular Weight]
464.48 |
| Chemical Properties | Back Directory | [Melting point ]
265-266℃ | [density ]
1.47 | [storage temp. ]
Store at -20°C | [solubility ]
≥23.05 mg/mL in DMSO; insoluble in H2O; ≥9.6 mg/mL in EtOH with gentle warming and ultrasonic | [form ]
solid |
| Hazard Information | Back Directory | [Uses]
SNX-2112 is a selective heat shock protein 90 (Hsp90) inhibitor which can exert a potent anticancer activity. Studies demonstates that SNX-2112 can exhibit a potent anticancer activity against B16 mel
anoma cells both in vitro and in vivo, by inhibiting cell proliferation and inducing cell cycle arrest and apoptosis in a mechanism dependent on the degredation of Hsp90 client proteins. | [target]
Hsp90α |
|
|